---
provider: perplexity
model: sonar-deep-research
cached: false
start_time: '2026-10-13T10:13:43.231168'
end_time: '2026-10-13T10:18:34.991549'
duration_seconds: 291.76
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: Cutis Laxa Autosomal Recessive Type 1A
  mondo_id: MONDO:0009052
  category: Mendelian
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    reasoning_effort: medium
    search_domain_filter: []
    return_citations: true
    temperature: 0.0
citation_count: 17
reference_validation:
  total_references: 4
  verified: 4
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  quotes_checked: 2
  quotes_valid: 2
  relevance_assessed: 4
  on_topic: 3
  validator_version: 0.3.0
term_validation:
  total_terms: 69
  verified: 63
  not_found: 2
  obsolete: 2
  unverifiable: 2
  confabulation_rate: 0.03
  labels_checked: 12
  labels_matching: 0
  labels_mismatched: 12
  mislabelled_terms:
  - term_id: NCIT:C15365
    reported_labels:
    - Respiratory therapy
    ontology_label: Outcomes Research
  - term_id: NCIT:C50683
    reported_labels:
    - Oxygen therapy
    ontology_label: Device Overstimulation
  - term_id: NCIT:C15402
    reported_labels:
    - Cardiac therapy
    ontology_label: Conization
  - term_id: NCIT:C71434
    reported_labels:
    - Vasodilator therapy
    ontology_label: COL4A5 wt Allele
  - term_id: NCIT:C307
    reported_labels:
    - Supportive care
    ontology_label: Biological Agent
  - term_id: NCIT:C18478
    reported_labels:
    - Palliative care
    ontology_label: Nanotechnology
  - term_id: NCIT:C15278
    reported_labels:
    - Angioplasty
    ontology_label: Modified Radical Mastectomy
  - term_id: NCIT:C15242
    reported_labels:
    - Stent placement
    ontology_label: Health Maintenance Organization
  - term_id: NCIT:C15795
    reported_labels:
    - Cardiac surgery
    ontology_label: Detection of Measurable Residual Disease
  - term_id: NCIT:C17564
    reported_labels:
    - Genetic counseling
    ontology_label: Guideline
  - term_id: NCIT:C17010
    reported_labels:
    - Prenatal diagnosis
    ontology_label: Prevalence
  - term_id: NCIT:C17302
    reported_labels:
    - Preimplantation genetic testing
    ontology_label: Histone Acetylase
  unresolved_terms:
  - HP:0004424
  - HP:0005118
  obsolete_terms:
  - term_id: HP:0001388
    ontology_label: obsolete Joint laxity
    replaced_by: HP:0001382
  - term_id: GO:0030433
    ontology_label: obsolete ubiquitin-dependent ERAD pathway
    replaced_by: GO:0036503
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Cutis Laxa Autosomal Recessive Type 1A
- **MONDO ID:** MONDO:0009052 (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Cutis Laxa Autosomal Recessive Type 1A** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Cutis Laxa, Autosomal Recessive, Type 1A (ARCL1A): Comprehensive Disease Characteristics and Mechanisms

Cutis laxa, autosomal recessive, type 1A (ARCL1A) is a very rare, life‑threatening Mendelian connective tissue disorder caused by biallelic pathogenic variants in the *FBLN5* gene, which encodes fibulin‑5, an extracellular matrix glycoprotein that is essential for elastic fiber assembly in skin, lung, vasculature, and other organs.[1][3][11][12][14] Clinically, ARCL1A is characterized by generalized cutis laxa with pendulous, inelastic skin evident from birth, accompanied by severe systemic manifestations including early childhood‑onset pulmonary emphysema, peripheral pulmonary artery stenosis, gastrointestinal and genitourinary diverticula, and other signs of generalized connective tissue fragility such as inguinal hernias.[1][2][3][14] Histopathology shows a marked reduction and disorganization of elastic fibers throughout the dermis, and ultrastructural analyses reveal abnormal elastin globules that fail to coalesce into normal elastic fiber cores, findings that are pathognomonic for autosomal recessive *FBLN5*‑related cutis laxa.[2][3][16] At the molecular level, recessive *FBLN5* mutations cause misfolding and intracellular retention of fibulin‑5, decreased secretion, and defective binding to tropoelastin and fibrillin‑1, thereby disrupting elastogenesis and triggering endoplasmic reticulum stress and increased apoptosis in fibroblasts.[12][14][16] The resulting elastic fiber deficiency leads to profound tissue laxity and loss of elastic recoil in the lungs and arteries, which in turn drives the major clinical complications of ARCL1A, particularly progressive respiratory failure due to emphysema and cardiopulmonary compromise from pulmonary artery stenosis and, occasionally, supravalvar aortic stenosis.[1][3][10][14] Prognosis is guarded, with cardiorespiratory failure in infancy or early childhood being a common cause of death, although intrafamilial variability in onset and severity is described.[1][3][14] Management is currently supportive and organ‑based, focusing on meticulous respiratory and cardiovascular care, surgical correction of hernias and diverticula, and genetic counseling of affected families, while research on fibulin‑5 biology and animal models is elucidating the mechanistic basis of elastic fiber pathology and may inform future targeted therapies.[12][13][14][15][16]  

---

## 1. Disease Information

### 1.1 Definition and Clinical Overview

Autosomal recessive cutis laxa type 1A (ARCL1A) is a specific subtype within the heterogeneous group of hereditary cutis laxa disorders, defined by generalized loose, wrinkled, and pendulous skin together with severe systemic involvement related to diffuse elastic fiber abnormalities.[1][2][3] Cutis laxa syndromes are collectively typified by reduced skin recoil and a prematurely aged appearance, but in ARCL1A these cutaneous manifestations are accompanied by life‑threatening visceral and vascular involvement, particularly pulmonary emphysema and peripheral pulmonary artery stenosis.[1][3][14] MedGen characterizes *FBLN5*‑related cutis laxa as presenting with cutis laxa, early childhood‑onset pulmonary emphysema, peripheral pulmonary artery stenosis, and hollow viscus diverticula, emphasizing that cardiorespiratory failure from pulmonary emphysema complications is the most common cause of death.[1] OMIM similarly summarizes autosomal recessive cutis laxa type I as a “specific, life‑threatening disorder with organ involvement, lung atelectasis and emphysema, diverticula of the gastrointestinal and genitourinary systems, and vascular anomalies,” with diminishment of elastic fibers throughout the dermis being pathognomonic.[3]  

Altmeyer’s dermatology resource describes hereditary cutis laxa as “a heterogeneous group of hereditary diseases whose main symptom is a pendulous, inelastic skin” due to loss, fragmentation, or severe disorganization of elastic fibers, and specifically notes that type IA is a life‑threatening form with pulmonary atelectasis/emphysema, gastrointestinal and urogenital diverticula, and pulmonary artery stenosis.[2] GeneReviews on *FBLN5*‑related cutis laxa (updated 2023) distinguishes autosomal recessive *FBLN5*‑related cutis laxa (ARCL1A) from the autosomal dominant cutis laxa type 2 (ADCL2) that is caused by different classes of *FBLN5* variants, highlighting that recessive variants lead to loss of function through protein misfolding and intracellular retention.[11][14] Taken together, these aggregated disease‑level resources converge on a definition of ARCL1A as a congenital, autosomal recessive elastic fiber disorder with generalized cutis laxa and severe cardiopulmonary and visceral involvement, driven by biallelic pathogenic variants in *FBLN5*.[1][3][11][14]  

### 1.2 Key Identifiers and Coding Systems

ARCL1A is catalogued across multiple genomic and clinical ontologies, which facilitates standardized annotation and integration into disease knowledge bases. OMIM lists “Cutis laxa, autosomal recessive, type IA” under entry number 219100, linked to the *FBLN5* gene (OMIM 604580) located on chromosome 14q32.12, and assigns phenotype mapping key “3” indicating that the molecular basis is known.[3] MedGen associates the concept “Cutis laxa, autosomal recessive, type 1A” with Concept ID C5848058, MedGen UID 1846304, and specifies that the MONDO term is MONDO:0009052, thereby anchoring the disease to the Monarch Initiative ontology.[1] ICD‑10 coding resources and Altmeyer’s dermatology site classify autosomal recessive cutis laxa type 1A under Q82.8, which covers other specified congenital malformations of the skin.[2]  

The *FBLN5*‑related cutis laxa GeneReview further links the condition to Orphanet and other rare disease catalogs, though these are not directly visible in the search results, and MedlinePlus Genetics assigns “FBLN5 gene” as the gene entry, explicitly noting that variants in *FBLN5* can cause autosomal recessive cutis laxa type 1A and autosomal dominant cutis laxa type 2.[11][14] NCBI’s Genetic Testing Registry (GTR) includes “Cutis laxa, autosomal recessive, type 1A” with reference to GeneReviews and testing options for *FBLN5*, providing a clinical genetics identifier.[4][14] In ontology frameworks, the primary disease term is MONDO:0009052, while the associated gene is HGNC:3600 (*FBLN5*), and the condition falls under the broader MONDO category of “heritable disorder of connective tissue.”[1][3][12][14]  

### 1.3 Synonyms and Alternative Names

ARCL1A has multiple synonyms that reflect historical nomenclature and classification across resources. MedGen lists synonyms including “ARCL1A” and “Autosomal recessive cutis laxa type IA,” corresponding to the autosomal recessive type I group.[1] OMIM uses the label “Cutis laxa, autosomal recessive, type IA” and notes that it falls within “type I autosomal recessive cutis laxa (ARCL1)”.[3] Altmeyer’s dermatology resource enumerates synonyms “ARCL1; ARCL1A; Autosomal recessive Cutis laxa, type 1A; Cutis laxa, autosomal recessive, type 1A; OMIM: 219100”.[2] GeneReviews refers to “autosomal recessive *FBLN5*‑related cutis laxa” as a synonym for ARCL1A, to emphasize the gene‑defined subtype within the broader cutis laxa phenotypic group.[14] For ontology mapping, “Cutis laxa, autosomal recessive, type 1A” and “Autosomal recessive cutis laxa type IA” are the preferred labels, with “FBLN5‑related cutis laxa (recessive form)” used in GeneReviews and MedlinePlus.[11][14]  

### 1.4 Source of Information: Aggregated Disease‑Level vs Individual Patient Data

The current understanding of ARCL1A is derived predominantly from aggregated disease‑level resources rather than large patient databases, reflecting the extreme rarity of the condition. MedGen, OMIM, GeneReviews, and GTR curate information across multiple case reports and small case series, summarizing clinical features, molecular mechanisms, and management recommendations based on the published literature.[1][3][4][14] For example, the original identification of *FBLN5* mutations in severe recessive cutis laxa arose from a consanguineous family described by Loeys et al. (2002), where homozygosity for a missense mutation (S227P) in fibulin‑5 caused severe cutis laxa with systemic involvement.[12][14][16] Subsequent mechanistic studies, such as Hu et al. (2006), examined fibroblasts from patients carrying the S227P variant to characterize misfolding and impaired elastic fiber incorporation.[16]  

Because ARCL1A is estimated to represent only a fraction of the already rare cutis laxa spectrum (overall prevalence ≈1:4,000,000 for all cutis laxa forms), large, structured electronic health record (EHR) datasets specific to this disease do not exist.[6] Instead, data come from individual clinical observations, small pedigrees, and a limited number of mechanistic studies using patient‑derived fibroblasts and animal models.[12][13][14][16] Therefore, the disease knowledge base entry must rely on curated summaries from these aggregated resources (GeneReviews, OMIM, MedGen, MedlinePlus) supplemented by original case reports and mechanistic studies, recognizing that many epidemiological parameters and detailed phenotypic frequencies remain imprecise due to small sample sizes.[1][3][11][14][16]  

---

## 2. Etiology

### 2.1 Primary Causal Factors: Genetic Basis

ARCL1A is unequivocally a monogenic, Mendelian disorder caused by biallelic (homozygous or compound heterozygous) pathogenic variants in *FBLN5*, which encodes fibulin‑5, an extracellular matrix glycoprotein that is central to elastic fiber assembly and integrin‑mediated signaling.[1][3][11][12][14] OMIM explicitly states that “autosomal recessive cutis laxa type IA (ARCL1A) is caused by homozygous or compound heterozygous mutation in the FBLN5 gene (604580) on chromosome 14q32,” underscoring the causal relationship.[3] GeneReviews confirms this, noting that the diagnosis of *FBLN5*‑related cutis laxa is established in a proband with characteristic clinical features and either biallelic pathogenic *FBLN5* variants (for autosomal recessive disease) or a heterozygous pathogenic variant (for autosomal dominant disease).[14] MedlinePlus Genetics likewise reports that variants in *FBLN5* can cause two types of cutis laxa—autosomal dominant cutis laxa type 2 (ADCL2) and autosomal recessive cutis laxa type 1A (ARCL1A)—and that autosomal recessive cutis laxa occurs when both copies of *FBLN5* are altered.[11]  

Fibulin‑5 (also termed DANCE/EVEC) is a secreted, calcium‑dependent extracellular matrix glycoprotein that organizes elastic fiber assembly by promoting coacervation and alignment of tropoelastin on microfibrils and tethering lysyl oxidase‑like enzymes to drive crosslinking.[12][13] The MIT FBLN5 resource summarizes that fibulin‑5 serves as a “central organizer of elastic fiber assembly” and functions as an integrin ligand coupling the matrix to intracellular signaling, with its deposition onto fibrillin‑1 microfibrils regulated by binding to latent transforming growth factor β binding protein‑2 (LTBP‑2).[12] Human genetic evidence firmly establishes the requirement for FBLN5 in elastogenesis: a homozygous S227P missense mutation in its fourth calcium‑binding EGF‑like domain causes autosomal recessive cutis laxa type I, while certain heterozygous tandem duplications cause autosomal dominant cutis laxa.[12][14][16]  

Pathogenic *FBLN5* variants in ARCL1A are predominantly missense mutations that alter conserved cysteine or serine residues in calcium‑binding epidermal growth factor‑like (cbEGF) domains, as well as nonsense variants that truncate the protein.[14][16] GeneReviews lists recessive variants including p.Cys144Trp, p.Cys217Arg (two families), p.Ser227Pro (two likely related families), and p.Glu391Ter, and notes that these recessive variants entail loss of function due to aberrant folding and intracellular retention.[14] Mechanistic studies show that recessive mutations such as C217R and S227P lead to misfolded fibulin‑5 that is poorly secreted, fails to incorporate into elastic fibers, and has reduced affinity for tropoelastin and fibrillin‑1, directly linking the genetic lesion to impaired elastic fiber formation.[16]  

### 2.2 Genetic Risk Factors Beyond Primary Causal Variants

For ARCL1A, the primary genetic risk factor is the inheritance of two pathogenic *FBLN5* alleles, typically in an autosomal recessive pattern with a 25% recurrence risk for each child of heterozygous carrier parents.[3][11][14] GeneReviews for *FBLN5*‑related cutis laxa and MedlinePlus Genetics both emphasize this autosomal recessive mechanism, noting that each sib of carrier parents has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.[11][14] In many reported families, consanguinity is present, reflecting increased risk of homozygosity for rare deleterious *FBLN5* alleles in populations with high rates of endogamy, although detailed population‑based data on consanguinity effects are limited.[12][14]  

Modifier genes that alter the severity or expressivity of ARCL1A have not been definitively identified, but the broader cutis laxa literature implicates genes involved in elastic fiber formation and connective tissue homeostasis, such as *PYCR1*, *LTBP4*, and *ATP6V0A2*, in other autosomal recessive cutis laxa subtypes.[2][5][6][9] For example, *LTBP4* mutations cause autosomal recessive cutis laxa type 1C with severe pulmonary emphysema and gastrointestinal involvement, while *ATP6V0A2* mutations cause autosomal recessive cutis laxa type 2A with neurologic and glycosylation‑related abnormalities.[6][9] Although these genes are not modifiers of *FBLN5*‑related disease per se, their involvement underscores a broader genetic network of elastic fiber and Golgi/secretory pathway components that may modulate phenotypes when co‑occurring variants are present; however, specific gene‑gene interaction data for ARCL1A remain sparse and largely hypothetical.[2][6][12][13][14]  

### 2.3 Environmental and Lifestyle Risk Factors

ARCL1A is not known to be caused by environmental exposures, infections, or lifestyle factors, as it is fundamentally a germline genetic disorder of elastic fiber assembly.[1][3][11][14] That said, environmental factors may influence disease severity or progression, particularly in organs where elastic fibers play a critical role in mechanical resilience. For instance, in individuals with underlying elastic fiber deficiency due to *FBLN5* mutations, exposure to cigarette smoke or air pollutants could reasonably be expected to exacerbate pulmonary emphysema by further damaging alveolar walls, although direct evidence specifically in ARCL1A is lacking and such interactions are inferred from general pulmonary pathophysiology rather than disease‑specific studies.[1][3][14] Similarly, systemic hypertension or high mechanical stress on the arterial system might conceivably accelerate aneurysm formation or vascular stenosis in the context of fragile elastic fibers, but again this is extrapolated from vascular biology rather than documented in ARCL1A cohorts.[13][15]  

Because ARCL1A patients often present in infancy or early childhood, environmental exposures that strongly influence adult pulmonary or vascular disease (such as long‑term smoking) are less likely to be major contributors to early disease onset. However, supportive recommendations to minimize respiratory irritants and optimize pulmonary health are reasonable in clinical practice given the underlying vulnerability of lung elastic tissue.[1][14] No occupational or toxic exposures have been implicated in ARCL1A pathogenesis, and there is no evidence of infectious agents triggering or causing the disease, distinguishing it sharply from acquired cutis laxa forms that may follow inflammatory or autoimmune conditions.[2][3]  

### 2.4 Protective Factors and Potential Modifiers

No genetic “protective variants” have been described that specifically mitigate the effects of *FBLN5* loss‑of‑function in ARCL1A, and given the essential role of fibulin‑5 in elastogenesis, complete protection is biologically implausible when both alleles are severely disrupted.[12][13][14][16] It is conceivable that individuals with milder hypomorphic *FBLN5* alleles could have less severe disease, but the few variants characterized to date (e.g., C217R, S227P, C144W, E391X) are strongly deleterious and associated with pronounced elastic fiber defects.[14][16]  

Environmental or lifestyle factors that might be considered protective are those that reduce secondary stress on vulnerable organs. For example, maintaining good respiratory hygiene, avoiding tobacco smoke and severe air pollution, prompt treatment of respiratory infections, and appropriate vaccinations may help reduce the cumulative burden on compromised lungs, thereby potentially slowing emphysema progression; however, these measures are generic and not demonstrated to prevent disease onset in ARCL1A.[1][14] In vascular tissues, strict blood pressure control and avoidance of extreme physical strain may be beneficial in reducing risk of aneurysm or dissection in individuals with known vascular anomalies, extrapolating from general management principles for connective tissue vasculopathies.[13][15] Nonetheless, these are supportive strategies rather than proven protective factors, and robust evidence specific to ARCL1A is currently lacking due to the rarity of the condition and absence of controlled studies.[1][3][14]  

### 2.5 Gene–Environment Interactions

Specific gene–environment interaction studies (GxE) for ARCL1A have not been reported in the literature or curated databases such as CTD, reflecting both the rarity of the disease and its clearly monogenic etiology.[1][3][11][14] In principle, the pathophysiology of *FBLN5*‑related cutis laxa could be influenced by environmental factors that affect elastic fiber turnover, oxidative stress, or inflammatory status in relevant tissues. For example, chronic exposure to oxidative stressors might aggravate elastic fiber degradation in the skin and lungs, while hypoxic conditions are known to upregulate FBLN5 expression in endothelial cells and participate in vascular remodeling.[15]  

The hypoxia‑driven regulation of FBLN5 illustrates a potential context in which gene–environment interactions could be meaningful: a study showed that fibulin‑5 is upregulated by hypoxia in endothelial cells and participates in vascular remodeling, controlling endothelial cell adhesion, motility, and proliferation.[15] In ARCL1A, where FBLN5 is dysfunctional or absent, hypoxia‑induced remodeling may be aberrant or insufficient, potentially contributing to vascular anomalies such as peripheral pulmonary artery stenosis and arterial tortuosity, though direct experimental demonstration in patients is lacking.[1][3][10][14][15]  

Given these considerations, gene–environment interactions in ARCL1A are best understood as hypothetical modifiers rather than causal determinants. Clinical guidance typically emphasizes mitigation of environmental stressors that target the lungs and vasculature, but mechanistic GxE studies remain an unmet research need.[1][14][15]  

---

## 3. Phenotypes

### 3.1 Overview of Phenotypic Spectrum

The phenotypic spectrum of ARCL1A encompasses generalized cutaneous laxity plus systemic manifestations affecting the respiratory, cardiovascular, gastrointestinal, genitourinary, and musculoskeletal systems, reflecting the widespread requirement for normal elastic fibers in connective tissue.[1][2][3][14] MedGen and OMIM highlight that FBLN5‑related cutis laxa is characterized by “wrinkled, redundant, inelastic and sagging skin” together with early childhood‑onset pulmonary emphysema, peripheral pulmonary artery stenosis, and hollow viscus diverticula of the intestine and bladder, among other signs of generalized connective tissue disorder such as inguinal hernias.[1][3] Altmeyer’s dermatology description, based on Papke et al. (2014), emphasizes that type IA autosomal recessive cutis laxa is a specific, life‑threatening disease with organ involvement including pulmonary atelectasis and emphysema, gastrointestinal and urogenital diverticula, and pulmonary artery stenosis, and notes cranial anomalies, delayed fontanel closure, joint flaccidity, hip luxation, and inguinal hernia as associated but less frequent features.[2]  

GeneReviews for *FBLN5*‑related cutis laxa elaborates on the clinical features and underscores intrafamilial variability in age of onset and severity, with some individuals presenting in the neonatal period and others later in infancy or childhood.[14] The cutaneous phenotype usually decreases somewhat in prominence with age, but systemic manifestations progress or become more apparent over time, particularly pulmonary emphysema and vascular anomalies.[1][3][14] Diminution and disorganization of elastic fibers throughout the dermis and abnormal elastin components on electron microscopy are considered pathognomonic for ARCL1A, distinguishing it from other connective tissue disorders such as Marfan syndrome and Ehlers‑Danlos syndrome, where skin elasticity is increased rather than decreased and the primary defect lies in different matrix components.[2][3][16]  

### 3.2 Cutaneous Phenotypes

The hallmark cutaneous feature of ARCL1A is generalized cutis laxa, defined as loose, wrinkled, inelastic skin that imparts a prematurely aged appearance.[1][2][3] Clinically, the skin appears pendulous and redundant, particularly in the face, neck, trunk, and extremities, with deep furrows and folds that are easily grasped and do not recoil promptly when stretched.[1][3] Altmeyer’s dermatology resource notes that the skin in hereditary cutis laxa is “pendulous, inelastic (in contrast to Marfan's syndrome and Ehlers‑Danlos syndrome)” and attributes these characteristics to loss, fragmentation, or severe disorganization of elastic fibers.[2] Histologically, electron microscopy shows a reduction of elastic fibers in the dermis and abnormal elastin components, which is pathognomonic for the autosomal recessive form.[2][3][16]  

Hu et al. analyzed skin sections from a patient with homozygous S227P mutation and reported “a lack of fibulin‑5 in the extracellular matrix and a concomitant disorganization of dermal elastic fibers,” with electron microscopy revealing a failure of elastin globules to fuse into a continuous elastic fiber core.[16] In their words:

> “Histological analysis of skin sections from a cutis laxa patient with a homozygous S227P mutation showed a lack of fibulin-5 in the extracellular matrix and a concomitant disorganization of dermal elastic fibers… By electron microscopy, elastic fibers in the skin of this patient showed a failure of elastin globules to fuse into a continuous elastic fiber core.” (PMID 17035250)[16]

Suggested HPO terms for cutaneous features include: Cutis laxa (HP:0000972), Redundant skin (HP:0001580), Prematurely aged appearance (HP:0003584), and Decreased skin elasticity (HP:0000975). The age of onset of cutis laxa is typically congenital or neonatal, with infants often noted at birth to have overfolded skin and enlarged fontanelles; severity can be marked in early life and may appear to lessen as children grow, although connective tissue fragility persists.[1][2][3][14] The quality‑of‑life impact of cutaneous manifestations includes cosmetic concerns, psychosocial stress, and potential functional issues such as skin irritation in folds, but in ARCL1A these are overshadowed by systemic complications.[1][14]  

### 3.3 Pulmonary Phenotypes

Pulmonary involvement is a central feature of ARCL1A and largely determines prognosis. MedGen and OMIM both emphasize early childhood‑onset pulmonary emphysema and lung atelectasis as key manifestations, with cardiorespiratory failure from complications of pulmonary emphysema being the most common cause of death.[1][3] GeneReviews notes that affected individuals typically develop severe emphysema, often in infancy or early childhood, manifested by progressive dyspnea, tachypnea, wheezing, and recurrent respiratory infections.[14] Imaging studies (chest X‑ray and computed tomography) typically reveal hyperinflated lungs, flattened diaphragms, and diffuse parenchymal destruction consistent with panacinar or centrilobular emphysema, although detailed radiologic descriptions are limited in the literature.[1][3][14]  

Mechanistically, fibulin‑5 deficiency leads to disorganized elastic fibers in alveolar walls, undermining the structural integrity and elastic recoil necessary to maintain normal lung architecture and ventilation.[13][16] Fbln5 knockout mice exhibit severe emphysematous changes, corroborating the role of fibulin‑5 in pulmonary elastic fiber homeostasis and providing an animal model that recapitulates human lung disease.[13] Suggested HPO terms include Pulmonary emphysema (HP:0006538), Respiratory insufficiency (HP:0002093), Recurrent respiratory infections (HP:0002205), and Tachypnea (HP:0002789). The age of onset of pulmonary involvement in ARCL1A is typically infancy or early childhood; progression is often rapid and severe, with many patients experiencing progressive respiratory failure despite supportive care.[1][3][14] The quality‑of‑life impact is profound, affecting physical functioning, ability to engage in normal activities, and often requiring oxygen supplementation and repeated hospitalizations.  

### 3.4 Cardiovascular and Vascular Phenotypes

Cardiovascular involvement in ARCL1A predominantly manifests as peripheral pulmonary artery stenosis and, less commonly, supravalvar aortic stenosis, as part of a generalized vasculopathy related to elastic fiber defects.[1][3][10][14] MedGen explicitly lists peripheral pulmonary artery stenosis among the core features of FBLN5‑related cutis laxa, noting that supravalvar aortic stenosis is occasionally observed.[1] OMIM similarly mentions vascular anomalies as part of the type I autosomal recessive cutis laxa spectrum, including pulmonary artery stenosis.[3] GeneReviews describes patients with ARCL1A who have significant peripheral pulmonary artery stenosis leading to right ventricular pressure overload, as well as those with supravalvar aortic stenosis that may require surgical intervention.[14]  

Fibulin‑5 is highly expressed in vascular tissues and plays a critical role in arterial elastic fiber formation and vasculogenesis.[12][13][15] Fibulin‑5 upregulation by hypoxia in endothelial cells supports its involvement in vascular remodeling and control of endothelial cell adhesion, motility, and proliferation, and suggests that defective fibulin‑5 may contribute to abnormal arterial structure and function.[15] Suggested HPO terms include Peripheral pulmonary artery stenosis (HP:0004424), Supravalvar aortic stenosis (HP:0004388), Arterial tortuosity (HP:0005118) if present, and Pulmonary hypertension (HP:0002092) as a potential consequence of stenotic lesions and emphysema. Onset of vascular complications may be congenital or early childhood, and severity varies; some patients manifest life‑threatening stenoses requiring surgery, while others have milder anomalies.[1][3][10][14][15] Cardiovascular involvement significantly impacts quality of life and survival, contributing to exercise intolerance, heart failure symptoms, and the need for invasive interventions.  

### 3.5 Gastrointestinal, Genitourinary, and Hernial Phenotypes

ARCL1A is associated with hollow viscus diverticula and hernias, reflecting generalized connective tissue weakness in the gastrointestinal and genitourinary tracts and abdominal wall.[1][2][3][14] MedGen notes “hollow viscus diverticula (e.g., intestine, bladder)” and “inguinal hernias” as evidence of generalized connective tissue disorder in FBLN5‑related cutis laxa.[1] OMIM similarly reports diverticula of the gastrointestinal and genitourinary systems and inguinal hernias among the manifestations of type I autosomal recessive cutis laxa.[3] Altmeyer’s dermatology description mentions diverticula of the gastrointestinal and urogenital system and inguinal hernia as observed features of ARCL1A, although it notes that inguinal hernia is relatively rare.[2]  

Suggested HPO terms include Intestinal diverticulum (HP:0005231), Bladder diverticulum (HP:0004381), Inguinal hernia (HP:0000023), and Umbilical hernia (HP:0001537) if present. The age of onset of diverticula and hernias may be childhood, often becoming apparent when complications such as pain, obstruction, or incarceration occur. Severity and progression vary, with some individuals requiring surgical repair to prevent serious complications such as perforation, obstruction, or strangulation.[1][3][14] Quality‑of‑life impact includes chronic discomfort, risk of emergencies, and limitations due to post‑surgical recovery or ongoing abdominal symptoms.  

### 3.6 Craniofacial, Skeletal, and Joint Phenotypes

ARCL1A can feature craniofacial anomalies, delayed closure of the fontanelles, joint laxity, and hip dislocation, though these are less consistent than cutaneous and pulmonary manifestations.[2][3][14] OMIM notes associated cranial anomalies, late closure of the fontanel, joint laxity, hip dislocation, and inguinal hernia as observed but uncommon features in autosomal recessive cutis laxa type I.[3] Altmeyer’s dermatology resource similarly records cranial anomalies, later closure of the fontanel, joint flaccidity, hip luxation, and inguinal hernia as associated but rare findings in type IA cutis laxa.[2] GeneReviews describes some ARCL1A patients with large anterior fontanelles that close late, as well as generalized joint hypermobility and occasional hip dislocation, likely reflecting elastic fiber defects in ligaments and periarticular tissues.[14]  

Suggested HPO terms include Large fontanelle (HP:0000260), Delayed closure of fontanelles (HP:0002650), Joint hypermobility (HP:0001388), Hip dislocation (HP:0002827), and Craniofacial dysmorphism terms such as Retrognathia (HP:0000278) if present. Age of onset is typically neonatal for fontanelle and craniofacial findings, and childhood for joint hypermobility and hip dislocation. Severity and frequency of these features are variable and generally less dominant than cardiorespiratory or cutaneous involvement.[2][3][14] Quality‑of‑life impact can include motor delays, pain due to joint instability, and need for orthopedic interventions.  

### 3.7 Neurological and Developmental Phenotypes

Unlike autosomal recessive cutis laxa type 2A (ATP6V0A2‑related), which is characterized by developmental delay, seizures, and neurologic regression, ARCL1A is not consistently associated with neurodevelopmental impairment.[5][6][9] GeneReviews and OMIM do not list developmental delay or seizures as typical features of ARCL1A, and patients reported with *FBLN5*‑related cutis laxa generally have normal intellectual development unless compromised secondarily by severe hypoxia from pulmonary disease.[3][14] By contrast, ATP6V0A2‑related cutis laxa is described as presenting with hypotonia, developmental delays, seizures, neurologic regression, and cortical and cerebellar malformations on MRI.[5][6][9]  

Therefore, suggested HPO terms for ARCL1A may generally exclude cognitive impairment unless there is case‑specific evidence, and neurological phenotypes should be carefully differentiated from those of ARCL2A and other cutis laxa syndromes. Quality‑of‑life impact related to neurodevelopmental status in ARCL1A is primarily driven by systemic disease and hospitalizations, rather than intrinsic brain malformations or seizures.[3][6][9][14]  

### 3.8 Phenotype Progression, Severity, and Frequency

ARCL1A exhibits a progressive course for systemic manifestations, particularly in the lungs and vasculature, while cutaneous findings may appear relatively more static or even slightly less prominent as children grow.[1][3][14] MedGen notes intrafamilial variability in age of onset, implying variable expressivity even among individuals with the same *FBLN5* mutation.[1] GeneReviews emphasizes that respiratory and cardiovascular complications often progress and may culminate in cardiorespiratory failure, whereas the skin phenotype may evolve but remains indicative of underlying elastic fiber deficiency.[14]  

The severity of ARCL1A ranges from perinatal lethality due to severe cardiopulmonary compromise to survival into childhood with significant morbidity, and possibly beyond in milder cases, though long‑term survival data are limited.[1][3][14] Frequency estimates for individual phenotypes (e.g., proportion of patients with supravalvar aortic stenosis or hip dislocation) are imprecise because the total number of reported cases is small. However, generalized cutis laxa and pulmonary emphysema appear to be highly penetrant and present in the majority of ARCL1A patients, while vascular anomalies, diverticula, and musculoskeletal features may be less consistent.[1][2][3][14]  

Quality‑of‑life impact varies with severity but is generally substantial due to chronic respiratory symptoms, limitations in physical activity, repeated medical interventions, and psychosocial issues related to appearance and disability. There are no disease‑specific quality‑of‑life instruments for ARCL1A, so generic measures such as SF‑36 or EQ‑5D would be used if studied; however, formal QoL assessments have not been published due to the rarity of the condition.[1][3][14]  

---

## 4. Genetic and Molecular Information

### 4.1 Causal Gene: *FBLN5* (Fibulin‑5)

The causal gene for ARCL1A is *FBLN5*, located on chromosome 14q32.12 and encoding fibulin‑5, a 448‑amino‑acid extracellular matrix glycoprotein belonging to the fibulin family.[1][3][11][12][14] OMIM associates cutis laxa, autosomal recessive, type IA (219100) with *FBLN5* (604580) and notes that homozygous or compound heterozygous variants in *FBLN5* cause ARCL1A.[3] MedGen likewise lists *FBLN5* (14q32.12) as the gene directly associated with “Cutis laxa, autosomal recessive, type 1A.”[1] MedlinePlus Genetics explains that *FBLN5* variants can cause autosomal dominant cutis laxa type 2 (ADCL2) or autosomal recessive cutis laxa type 1A (ARCL1A), and details the functional consequences of these variants on fibulin‑5 and elastic fiber assembly.[11]  

Fibulin‑5 is characterized as a “central organizer of elastic fiber assembly” and an integrin ligand that couples the extracellular matrix to intracellular signaling.[12] It promotes coacervation and alignment of tropoelastin on microfibrils and tethers lysyl oxidase‑like enzymes LOXL1, LOXL2, and LOXL4 to drive crosslinking of tropoelastin into mature elastin fibers.[12][13] Its deposition onto fibrillin‑1 microfibrils is regulated by direct binding to LTBP‑2, which determines whether fibulin‑5 and elastin assemble in a fibrillin‑1‑dependent or ‑independent manner.[12] Functionally, fibulin‑5 is essential for elastogenesis in multiple tissues, including skin, lung, and vasculature, and its importance is underscored by human genetic evidence and animal models.[12][13][14][16]  

Suggested gene ontology (GO) terms for *FBLN5* include extracellular matrix organization (GO:0030198), elastic fiber assembly (GO:0071689), cell adhesion (GO:0007155), and regulation of cell migration (GO:0030334). The gene symbol is *FBLN5* (HGNC:3600), and the protein is also known as DANCE (Developmental Arteries and Neural crest EGF‑like), with UniProt accession Q9UBX5 in humans.[12][14]  

### 4.2 Pathogenic Variant Classes and Functional Consequences

Pathogenic *FBLN5* variants associated with ARCL1A are primarily missense mutations affecting conserved residues within calcium‑binding EGF‑like domains, as well as nonsense variants that truncate the protein.[14][16] GeneReviews lists several autosomal recessive pathogenic variants including p.Cys144Trp, p.Cys217Arg, p.Ser227Pro, and p.Glu391Ter, noting that these cause loss of function through aberrant folding and intracellular retention.[14] The MIT FBLN5 gene resource describes the S227P missense mutation in the fourth calcium‑binding EGF‑like domain as causing autosomal recessive cutis laxa type I and demonstrating that FBLN5 function is required for normal elastogenesis.[12]  

Hu et al. investigated two disease‑causing missense substitutions, C217R and S227P, to elucidate mechanisms of impaired elastic fiber formation in recessive cutis laxa.[16] They found that S227P mutant fibulin‑5 was synthesized and secreted at a reduced rate compared with wild‑type protein, that both mutants failed to be incorporated into elastic fibers, and that recombinant mutant fibulin‑5 showed reduced affinity for tropoelastin and impaired association with fibrillin‑1 microfibrils.[16] Moreover, S227P triggered an endoplasmic reticulum stress response and increased apoptosis in patient fibroblasts. Hu et al. concluded:

> “We conclude that recessive cutis laxa mutations in fibulin-5 result in misfolding, decreased secretion and a reduced interaction with elastin and fibrillin-1 leading to impaired elastic fiber development.” (PMID 17035250)[16]

Thus, ARCL1A variants are best classified as germline, loss‑of‑function alleles that act via protein misfolding and failure of secretion rather than dominant negative mechanisms. In contrast, autosomal dominant *FBLN5* variants cause ADCL2 by elongating the protein in a way that allows it to remain stable and exert dominant‑negative effects on elastic fiber assembly.[11][14] GeneReviews summarizes this distinction by noting that dominant pathogenic variants lead to protein elongation and dominant‑negative action, whereas recessive variants entail loss of function due to aberrant folding and retention in the endoplasmic reticulum.[14]  

Most described ARCL1A variants are pathogenic or likely pathogenic by ACMG/AMP criteria, given their segregation in affected families, absence or extreme rarity in population databases, and strong functional evidence of impaired elastin binding and fiber incorporation.[14][16] Allele frequencies in gnomAD and other population datasets are extremely low, consistent with the rarity of the disease, but precise numeric frequencies for specific variants are not detailed in the retrieved resources.[6][11][14]  

### 4.3 Modifier Genes and Genetic Heterogeneity in Cutis Laxa Spectrum

While *FBLN5* mutations cause ARCL1A, genetic heterogeneity in the broader cutis laxa spectrum involves multiple other genes that produce overlapping phenotypes, underscoring a common mechanistic axis of elastic fiber and secretory pathway defects.[2][3][5][6][7][9] Autosomal recessive cutis laxa type 1B (ARCL1B) is caused by biallelic *EFEMP2* variants, leading to cutis laxa with arterial tortuosity, aneurysms, and systemic involvement.[7] Autosomal recessive cutis laxa type 1C involves *LTBP4* mutations, while autosomal recessive type 2A (ARCL2A; Debré‑type cutis laxa) is caused by *ATP6V0A2* mutations affecting Golgi acidification and protein glycosylation.[5][6][9]  

The ATP6V0A2‑related cutis laxa GeneReview notes that *ATP6V0A2* encodes the α2 subunit of the V‑type proton ATPase, and that its loss leads to generalized cutis laxa, developmental delays, seizures, and cortical malformations.[6] MedGen describes ARCL2A as representing a spectrum of entities with variable severity of cutis laxa, abnormal growth, developmental delay, and skeletal abnormalities, and notes that nearly all affected individuals have developmental delays, seizures, and neurologic regression.[9] EFEMP2‑related cutis laxa (ARCL1B) is characterized by cutis laxa plus arterial tortuosity, aneurysms, stenosis, retrognathia, joint laxity, and arachnodactyly, with severity ranging from perinatal lethality to forms limited to vascular and craniofacial systems.[7]  

Although these genes do not modify *FBLN5*‑related disease directly, their roles highlight a network of proteins critical for elastic fiber assembly, ECM organization, and Golgi function. This suggests that subtle variants in related pathways could theoretically influence ARCL1A severity, but specific modifier genes have not yet been identified or validated for *FBLN5*‑related cutis laxa.[2][3][6][7][9][12][13][14]  

### 4.4 Epigenetic Information and Chromosomal Abnormalities

No epigenetic abnormalities such as DNA methylation changes, histone modifications, or chromatin structure alterations have been reported as primary drivers of ARCL1A, and given the clear Mendelian etiology based on *FBLN5* variants, epigenetic mechanisms are not considered central to disease pathogenesis.[1][3][11][14] Likewise, chromosomal abnormalities such as aneuploidy, translocations, inversions, or large copy number variations have not been implicated in ARCL1A, and the molecular defect resides at the single‑gene level rather than involving structural rearrangements.[3][14] Chromosomal microarray and karyotyping are therefore of limited utility for diagnosing ARCL1A, unless performed as part of broader evaluation for unexplained syndromic features before the identification of a *FBLN5* variant.[4][14]  

---

## 5. Environmental Information

### 5.1 Non‑Genetic Contributing Factors

In ARCL1A, environmental factors do not cause the disease but may modulate the course by interacting with intrinsically fragile elastic fibers and compromised organ systems. For the lungs, exposures such as cigarette smoke, indoor and outdoor air pollution, and recurrent respiratory infections could theoretically accelerate the progression of emphysema and respiratory failure in individuals with underlying fibulin‑5 deficiency, as these factors are known to damage alveolar structures and increase inflammatory burden in chronic obstructive pulmonary disease.[1][3][14] However, ARCL1A patients often present with severe emphysema early in life, before substantial cumulative exposure to such factors, so the primary driver remains the genetic defect and consequent failure of elastogenesis.[1][3][13][14]  

For the vasculature, hypertension and mechanical stress may exacerbate arterial tortuosity or aneurysm expansion in the setting of weakened elastic fibers, extrapolating from general connective tissue vasculopathies such as Marfan syndrome. Yet, specific evidence for such interactions in ARCL1A is lacking, and vascular anomalies are largely congenital or early developmental manifestations of fibulin‑5 dysfunction.[1][3][13][14][15] No toxins, radiation exposures, or occupational hazards have been identified as causal or strongly contributory factors for ARCL1A, distinguishing it clearly from acquired cutis laxa, which can arise after inflammatory, autoimmune, or drug‑induced insults.[2][3]  

### 5.2 Lifestyle Factors and Infectious Agents

Lifestyle factors, particularly smoking, are discouraged for ARCL1A patients due to general pulmonary health considerations, but they are not causative of the disease. Nutrition, exercise, and general wellness practices have no specific documented protective or harmful effects beyond their broad influence on overall health and resilience.[1][14] Infectious agents do not cause ARCL1A, although respiratory infections can precipitate acute decompensation in patients with severe emphysema and pulmonary artery stenosis. Accordingly, routine vaccinations (influenza, pneumococcal) and prompt treatment of infections are recommended as part of supportive care, based on general clinical practice rather than disease‑specific studies.[1][14]  

---

## 6. Mechanism and Pathophysiology

### 6.1 Ordered Causal Chain from Mutation to Clinical Manifestation

The pathophysiology of ARCL1A can be conceptualized as a chain of causally linked steps, beginning with germline *FBLN5* mutations and culminating in multi‑organ clinical manifestations. The core mechanistic steps, integrating established and inferred processes, are as follows:

Step 1: Biallelic pathogenic variants in *FBLN5* result in misfolding of fibulin‑5, decreased secretion, and intracellular retention in the endoplasmic reticulum of fibroblasts and other ECM‑producing cells, leading to loss of functional fibulin‑5 in the extracellular matrix.[11][12][14][16]  

Step 2: Loss of functional fibulin‑5 leads to impaired elastic fiber assembly, including reduced coacervation and alignment of tropoelastin on microfibrils, diminished tethering of lysyl oxidase‑like enzymes, and defective deposition of elastin onto fibrillin‑1 microfibrillar scaffolds, resulting in fragmented, disorganized, or absent elastic fibers in connective tissues.[12][13][16]  

Step 3: Disorganized or deficient elastic fibers in the dermis cause reduced skin elasticity, leading to generalized cutis laxa with redundant, sagging skin and a prematurely aged appearance, as documented histologically and ultrastructurally.[2][3][16]  

Step 4: In the lungs, elastic fiber failure in alveolar septa and small airways leads to loss of alveolar structural integrity and elastic recoil, resulting in progressive airspace enlargement, destruction of alveolar walls, and early‑onset pulmonary emphysema with respiratory insufficiency.[1][3][13][14]  

Step 5: In the vasculature, defective elastic fibers in arterial walls impair normal elastic lamellae and vessel compliance, predisposing to vascular anomalies such as peripheral pulmonary artery stenosis and, occasionally, supravalvar aortic stenosis or arterial tortuosity, with altered hemodynamics and risk of cardiopulmonary compromise.[1][3][10][13][14][15]  

Step 6: In hollow viscera (intestine, bladder) and abdominal wall structures, connective tissue weakness due to elastic fiber deficiency leads to diverticula formation and hernias, reflecting local protrusions where mechanical stress acts on weakened ECM.[1][2][3][14]  

Step 7: Persistent ER stress and increased apoptosis in fibroblasts due to misfolded fibulin‑5 may contribute to broader connective tissue degeneration and impaired matrix maintenance over time, potentially amplifying systemic manifestations beyond the initial elastogenesis defect.[15][16]  

Step 8: The culmination of these tissue‑level abnormalities in skin, lung, vasculature, and viscera leads to the characteristic clinical syndrome of ARCL1A, with generalized cutis laxa, severe pulmonary emphysema, vascular stenosis, diverticula, and hernias, and ultimately cardiorespiratory failure as the major determinant of prognosis.[1][3][14]  

Steps 1–3 and 4–6 are strongly supported by human fibroblast studies, histopathology, and animal models, whereas Steps 7 and some aspects of Step 5 are inferred from mechanistic data in endothelial cells and general ECM biology rather than directly demonstrated in ARCL1A patients.[13][15][16]  

### 6.2 Molecular Pathways: Elastogenesis and ECM Organization

Fibulin‑5 functions within molecular pathways governing elastogenesis and extracellular matrix organization. Elastogenesis involves tropoelastin synthesis, secretion, coacervation (self‑assembly into aggregates), alignment on microfibrillar scaffolds, and crosslinking by lysyl oxidase‑like enzymes to form mature elastic fibers.[12][13] Fibulin‑5 serves as an elastogenic scaffold that promotes tropoelastin coacervation and alignment on fibrillin‑rich microfibrils, and tethers LOXL1, LOXL2, and LOXL4 enzymes to facilitate crosslinking, integrating structural and enzymatic components of elastic fiber assembly.[12][13]  

The MIT FBLN5 resource notes that fibulin‑5 is both an elastin‑binding and integrin‑binding protein, placing it upstream of MAPK signaling and connecting ECM scaffolding to intracellular pathways.[12] Through its interaction with integrins, particularly αvβ3 and αvβ5, fibulin‑5 influences cell adhesion, migration, and proliferation, which may be relevant to vascular remodeling and tissue homeostasis.[12][15] Its deposition on fibrillin‑1 microfibrils is regulated by binding to LTBP‑2, which controls whether fibulin‑5 and elastin assemble in fibrillin‑dependent or independent manners.[12]  

Loss of fibulin‑5 in ARCL1A disrupts these pathways, resulting in defective elastogenesis. GO processes implicated include elastic fiber assembly (GO:0071689), extracellular matrix organization (GO:0030198), collagen fibril organization (GO:0030199, though elastin‑specific here), and cell adhesion (GO:0007155). At the pathway level, Reactome and KEGG would classify fibulin‑5 as part of ECM‑receptor interaction and cell–ECM communication pathways, although specific curated pathways for FBLN5 may not yet be detailed. The failure of elastogenesis underlies widespread tissue mechanical defects, including reduced elasticity and increased susceptibility to mechanical failure in skin, lungs, and arteries.[12][13][16]  

### 6.3 Cellular Processes: Misfolding, ER Stress, and Apoptosis

At the cellular level, recessive *FBLN5* mutations lead to misfolded fibulin‑5 accumulating in the endoplasmic reticulum, triggering ER stress responses and apoptosis in fibroblasts.[16] Hu et al. showed that the S227P mutation caused strong co‑localization of mutant fibulin‑5 with ER folding chaperones such as calreticulin, BiP (immunoglobulin‑binding protein), and protein disulfide isomerase, consistent with misfolded protein retention.[16] They also observed increased rates of apoptosis in patient fibroblasts relative to controls. These findings indicate activation of the unfolded protein response (UPR) and ER quality control pathways, leading to cell stress and death when misfolded fibulin‑5 cannot be properly refolded or degraded.[16]  

ER stress and apoptosis may contribute to reduced fibroblast numbers or functional capacity, compounding the primary defect in elastogenesis and impairing ongoing ECM maintenance. GO terms relevant to these processes include protein folding (GO:0006457), response to unfolded protein (GO:0006986), ER‑associated protein catabolic process (GO:0030433), and apoptotic process (GO:0006915). Although these cell‑level phenomena are well documented in vitro, their systemic impact in ARCL1A remains inferred, as there are no direct in vivo studies of fibroblast dynamics in patients. Nevertheless, chronic ER stress is likely to exacerbate connective tissue fragility and may contribute to disease progression.[15][16]  

### 6.4 Protein Dysfunction: Misfolding, Loss of Function, and Failed Elastic Fiber Incorporation

Fibulin‑5 protein dysfunction in ARCL1A is characterized by misfolding, reduced secretion, and failure to incorporate into elastic fibers. Hu et al. demonstrated that S227P and C217R mutations reduce the rate of fibulin‑5 secretion, decrease its affinity for tropoelastin, and impair its association with fibrillin‑1 microfibrils.[16] As a result, mutant fibulin‑5 fails to participate in elastic fiber assembly, leaving elastin globules unorganized and unfused into continuous cores. Electron microscopy of patient skin confirmed this, showing isolated elastin globules rather than continuous elastic fibers, a hallmark of failed elastogenesis.[16]  

MedlinePlus Genetics describes recessive *FBLN5* variants as causing autosomal recessive cutis laxa by changing single amino acids in fibulin‑5, which “alter the structure of the protein, trapping it within the cell… Because the defective fibulin‑5 never makes it to the extracellular matrix, it is not available for the assembly of elastic fibers.”[11] GeneReviews echoes this mechanism, noting that recessive pathogenic variants cause loss of function due to aberrant folding and intracellular retention.[14] In contrast, dominant *FBLN5* variants produce elongated proteins that remain secreted and act in a dominant‑negative manner, interfering with normal elastic fiber assembly despite the presence of one normal allele.[11][14]  

Functionally, ARCL1A is thus a prototypical loss‑of‑function disorder, with fibulin‑5 misfolding and ER retention preventing it from executing its elastogenic and integrin‑binding roles. This protein dysfunction is central to the pathophysiology and provides a mechanistic link between genotype and ECM phenotype.[12][14][16]  

### 6.5 Tissue Damage Mechanisms: Loss of Elasticity, Mechanical Failure, and Organ Remodeling

The tissue damage in ARCL1A stems from the mechanical consequences of defective elastic fibers. In the skin, loss of elastic recoil leads to persistent stretching and sagging under gravity, with dermal collagen and other matrix elements unable to fully compensate for the absence of elastin’s elastic return. Histopathology shows a dermis with markedly reduced and disorganized elastic fibers, while collagen networks remain relatively intact, implying that the primary defect is specific to elastin components.[2][3][16]  

In the lungs, elastic fibers in alveolar walls are crucial for maintaining lung architecture and for passive recoil during exhalation. Fibulin‑5 deficiency in Fbln5 knockout mice leads to malformed elastic fibers and a tendon‑specific increase in elastic modulus, illustrating the role of elastic fibers in tissue mechanics.[13] In lung tissue, similar defects cause alveolar wall weakening, leading to airspace enlargement (emphysema) and impaired gas exchange, with associated hypoxia and respiratory insufficiency.[1][3][13][14]  

In arteries, elastic lamellae in the media provide resilience and energy storage during cardiac cycles. Defective elastic fibers in ARCL1A compromise vessel compliance, leading to abnormal flow patterns and structural changes such as stenosis or aneurysm formation. Fibulin‑5’s role in vascular remodeling, particularly its upregulation under hypoxic conditions in endothelial cells, suggests that its absence may impair adaptive responses to hemodynamic stress, further contributing to vascular pathology.[13][15]  

Tissue damage mechanisms thus involve a combination of mechanical failure due to defective elastic fibers, maladaptive remodeling responses, and secondary consequences such as hypoxia, pressure overload, and organ dysfunction. GO terms relevant to these processes include regulation of blood vessel morphogenesis (GO:1901342), lung development (GO:0030324), and response to mechanical stimulus (GO:0009612).  

### 6.6 Immune System Involvement and Metabolic Changes

Direct immune system involvement (autoimmunity or immunodeficiency) is not a recognized component of ARCL1A. There is no evidence of autoimmune attack on elastic fibers or systemic inflammatory disease driving cutis laxa in this genetic subtype, distinguishing it from acquired cutis laxa forms that may follow inflammatory episodes.[2][3] Any local inflammatory responses are likely secondary to tissue damage and mechanical stress, rather than primary drivers of disease. Similarly, there are no specific metabolic changes (e.g., enzyme deficiencies, lipid metabolism abnormalities) implicated in ARCL1A beyond those associated with ECM turnover and ER stress in fibroblasts.[15][16]  

In contrast, ATP6V0A2‑related cutis laxa (ARCL2A) features a metabolic component involving disrupted Golgi acidification and glycosylation pathways, leading to congenital disorders of glycosylation and systemic metabolic consequences.[6][9] However, these mechanisms are distinct from the fibulin‑5‑centric pathophysiology in ARCL1A and highlight the heterogeneity of cutis laxa syndromes rather than a shared metabolic defect.  

### 6.7 Epigenetic Changes and Molecular Profiling

No epigenetic alterations have been reported as primary or secondary drivers in ARCL1A, and molecular profiling studies (transcriptomics, proteomics, metabolomics, lipidomics) specific to this disease have not been published, likely due to its rarity.[1][3][14] Some insights into fibulin‑5 expression regulation come from studies of hypoxia‑induced upregulation in endothelial cells and its role in vasculogenesis and vascular remodeling.[15] These studies suggest that FBLN5 expression is responsive to environmental cues and may be regulated by hypoxia‑inducible factors, but they do not reveal epigenetic abnormalities unique to ARCL1A.  

Large‑scale multi‑omics integration efforts such as TCGA and ICGC focus primarily on cancer and common diseases and have not included ARCL1A. Functional genomics screens, CRISPR or RNAi‑based, targeting fibulin‑5 have not been reported in the context of cutis laxa. Thus, molecular profiling and advanced functional genomics remain underexplored areas for ARCL1A research.[12][13][15][16]  

### 6.8 Cell Types and Ontology Terms

The key cell types involved in ARCL1A pathophysiology are fibroblasts (CL:0000057), smooth muscle cells (CL:0000168), endothelial cells (CL:0000115), and pulmonary epithelial cells (e.g., type II pneumocytes, CL:0002062). Fibroblasts in the dermis and other connective tissues are responsible for producing fibulin‑5 and assembling elastic fibers; endothelial and smooth muscle cells in arterial walls rely on fibulin‑5 for proper elastic lamellae and vessel structure; and pulmonary epithelial and interstitial cells depend on intact elastic fibers to maintain alveolar architecture.[12][13][15][16]  

Anatomical ontology terms include skin (UBERON:0002097), dermis (UBERON:0002067), lung (UBERON:0002048), pulmonary alveolus (UBERON:0002299), pulmonary artery (UBERON:0001638), aorta (UBERON:0000947), intestine (UBERON:0002114), urinary bladder (UBERON:0001255), and abdominal wall (UBERON:0003688). Subcellular GO cellular component terms include extracellular matrix (GO:0031012), elastic fiber (GO:0071953), endoplasmic reticulum (GO:0005783), and secretory granule lumen (GO:0030778) for secreted ECM proteins.  

---

## 7. Anatomical Structures Affected

### 7.1 Organ‑Level Involvement

ARCL1A affects multiple organ systems, reflecting the ubiquitous role of elastic fibers in maintaining tissue integrity and elasticity. The primary organs directly involved are the skin, lungs, and arteries, with secondary involvement of gastrointestinal and genitourinary tracts and musculoskeletal structures.[1][2][3][14]  

The skin (UBERON:0002097) is universally involved, with generalized cutis laxa due to defective dermal elastic fibers.[2][3][16] The lungs (UBERON:0002048) are severely affected, particularly the pulmonary alveoli (UBERON:0002299), where elastic fiber failure leads to emphysema and respiratory insufficiency.[1][3][13][14] The cardiovascular system (UBERON:0004535) is impacted through peripheral pulmonary artery stenosis (pulmonary arteries, UBERON:0001638) and supravalvar aortic stenosis (ascending aorta, UBERON:0000947), causing hemodynamic compromise and potential heart failure.[1][3][10][14][15]  

Secondary organ involvement includes the gastrointestinal tract (intestine, UBERON:0002114), where diverticula form due to connective tissue weakness, and the urinary bladder (UBERON:0001255), which can develop diverticula as well.[1][2][3][14] The abdominal wall (UBERON:0003688) is affected by hernias, particularly inguinal hernias, reflecting weakness in the fascial and muscular layers. Musculoskeletal involvement includes joints (UBERON:0000982) and hip joints (UBERON:0001464), where joint laxity and hip dislocation may arise from defective ligaments and periarticular connective tissue.[2][3][14]  

### 7.2 Tissue and Cell‑Level Involvement

At the tissue level, ARCL1A primarily affects connective tissue, especially elastic fiber‑containing ECM domains. In the skin, dermal connective tissue (UBERON:0002067) exhibits reduced elastic fibers and abnormal elastin components, as shown by electron microscopy.[2][3][16] Collagen bundles are relatively preserved, highlighting specificity for elastin-related components. In the lungs, interstitial connective tissue and alveolar septa contain abnormal elastic fibers, leading to weaker parenchymal scaffolding.[13][16] In arteries, the tunica media’s elastic lamellae are compromised, affecting the mechanical behavior of vascular tissue.[12][13][15]  

Cell types central to disease include fibroblasts (CL:0000057), which synthesize fibulin‑5 and other ECM proteins; vascular smooth muscle cells (CL:0000168), which interact with elastic lamellae; endothelial cells (CL:0000115), which rely on ECM cues for angiogenesis and remodeling; and pulmonary epithelial and interstitial cells that depend on ECM for structural support.[12][13][15][16] Fibroblast dysfunction due to ER stress and misfolded fibulin‑5 is particularly central, leading to impaired ECM production and maintenance.[16]  

### 7.3 Subcellular Compartments

Subcellular compartments involved in ARCL1A include the endoplasmic reticulum (ER; GO:0005783), where fibulin‑5 is synthesized and folded; the secretory pathway (Golgi apparatus, GO:0005794), which traffics fibulin‑5 to the extracellular space; and the extracellular matrix (ECM; GO:0031012), where fibulin‑5 orchestrates elastogenesis. Mutant fibulin‑5 in ARCL1A accumulates in the ER due to misfolding, triggers ER stress and UPR responses, and fails to be properly processed or secreted.[16]  

In normal cells, fibulin‑5 would localize to elastic fibers (GO:0071953) within the ECM, interacting with elastin, fibrillin‑1, LTBP‑2, and integrins. In ARCL1A, this localization is absent, and the ECM lacks fibulin‑5‑mediated scaffolding, leading to disorganized elastic fiber deposition and mechanical defects.[12][13][16]  

### 7.4 Localization and Lateralization

ARCL1A manifestations are generally bilateral and systemic rather than localized or unilateral. Cutis laxa affects the skin globally, though anatomical regions such as the face, neck, and flexural areas may appear most conspicuous.[2][3] Pulmonary emphysema involves both lungs, often diffusely, though regional differences in severity may exist depending on ventilation patterns and local mechanical stresses.[1][3][13][14] Peripheral pulmonary artery stenosis can involve multiple branch pulmonary arteries, sometimes asymmetrically, but the disease does not show a consistent side preference.[1][10][14]  

Vascular anomalies such as supravalvar aortic stenosis are centrally located, and diverticula in the intestine and bladder can occur at multiple sites depending on local structural weaknesses and mechanical forces.[1][2][3][14] Joint laxity and hip dislocation can be bilateral or unilateral, depending on specific ligamentous involvement and developmental factors.[2][3][14] Overall, ARCL1A is best characterized as a systemic, bilateral connective tissue disease affecting multiple anatomical sites rather than one with defined lateralization patterns.  

---

## 8. Temporal Development

### 8.1 Age of Onset and Onset Pattern

ARCL1A is generally congenital or neonatal in onset for cutaneous and craniofacial features, with systemic manifestations unfolding during infancy and early childhood. MedGen and OMIM note that cutis laxa is present early, with wrinkled, redundant, sagging skin evident in infancy.[1][3] Altmeyer’s dermatology and GeneReviews describe infants with overfolded skin, enlarged fontanelles, and distinctive facial features consistent with hereditary cutis laxa.[2][14]  

Pulmonary emphysema and peripheral pulmonary artery stenosis typically manifest in early childhood, although severe forms may be recognized in infancy when respiratory distress and failure occur. MedGen specifically mentions “early childhood‑onset pulmonary emphysema” as a defining feature of FBLN5‑related cutis laxa.[1] The onset pattern is chronic and insidious for emphysema, with progressive worsening of respiratory symptoms rather than acute episodes, although respiratory infections can precipitate sudden decompensation. Vascular anomalies such as pulmonary artery stenosis and supravalvar aortic stenosis may be congenital but become clinically apparent as children grow and symptoms such as cyanosis or exercise intolerance emerge.[1][3][10][14]  

### 8.2 Disease Progression and Course

The course of ARCL1A is typically progressive, especially with respect to pulmonary and cardiovascular manifestations. OMIM and GeneReviews emphasize that cardiorespiratory failure from complications of pulmonary emphysema is the most common cause of death, indicating progressive lung destruction over time.[1][3][14] Intrafamilial variability in age of onset suggests that some individuals progress more rapidly than others, possibly due to differences in environmental exposures, comorbidities, or subtle genetic modifiers.[1][14]  

Cutaneous laxity may appear most dramatic in infancy and early childhood and may seem less pronounced relative to body size as children grow, but histologic elastic fiber defects persist and cutaneous fragility remains.[2][3][16] Diverticula and hernias may develop or enlarge with age, reflecting cumulative mechanical stress on weakened connective tissue. Vascular anomalies can progress, with stenoses worsening or aneurysms enlarging, contributing to increased risk of heart failure or vascular complications. In the absence of disease‑modifying treatments, ARCL1A is a chronic, lifelong condition, with many patients experiencing serious complications in childhood and adolescence.[1][3][14]  

### 8.3 Remission Patterns and Critical Periods

ARCL1A does not typically exhibit remission in the sense of disease disappearance, as the underlying genetic defect and elastogenesis failure are persistent. However, the relative prominence of certain manifestations, particularly cutaneous laxity, may change over time; skin may appear somewhat less redundant in older children compared to infants, although connective tissue fragility persists.[2][3][14][16] No treatment‑induced remission has been documented, and supportive therapies primarily aim to stabilize or slow progression rather than reverse structural defects.  

Critical periods in ARCL1A include the neonatal and early childhood phases, when the risk of severe respiratory failure and cardiopulmonary complications is highest. Early recognition and intervention during these periods can be crucial for survival, allowing prompt management of emphysema and vascular stenosis and appropriate surgical interventions for hernias or diverticula.[1][3][14] Genetic counseling and prenatal diagnosis represent critical opportunities for primary prevention in families with known *FBLN5* variants.  

---

## 9. Inheritance and Population

### 9.1 Inheritance Pattern, Penetrance, and Expressivity

ARCL1A follows an autosomal recessive inheritance pattern, with affected individuals carrying biallelic pathogenic variants in *FBLN5*.[1][3][11][14] OMIM emphasizes that autosomal recessive cutis laxa type IA is caused by homozygous or compound heterozygous mutations in *FBLN5*.[3] GeneReviews and MedlinePlus Genetics note that both *FBLN5* alleles must be altered to result in the autosomal recessive form of cutis laxa, and that heterozygous carriers are typically asymptomatic.[11][14]  

Penetrance in ARCL1A appears to be high or complete among individuals with clearly deleterious *FBLN5* variants, as reported families show consistent disease in homozygous individuals.[12][14][16] However, expressivity is variable, with intrafamilial differences in age of onset, severity of emphysema, presence or absence of vascular anomalies, and extent of diverticula and hernias.[1][3][14] GeneReviews specifically mentions intrafamilial variability, highlighting that not all individuals with the same mutation have identical clinical profiles.[14]  

There is no evidence of genetic anticipation in ARCL1A, as the disease is not associated with repeat expansions or dynamic mutations that lengthen over generations. Germline mosaicism has not been reported but could theoretically occur, particularly in cases where multiple children in a family are affected despite negative parental testing; however, no such case has been documented in the retrieved resources.[3][14]  

### 9.2 Epidemiology, Prevalence, and Incidence

ARCL1A is extremely rare, and precise prevalence and incidence estimates are not available. The ATP6V0A2‑related cutis laxa GeneReview cites an estimated prevalence of all types of cutis laxa as 1:4,000,000 based on the Rhône‑Alpes Eurocat registry, attributing this figure to E. Robert’s personal observation.[6] ARCL1A constitutes only a subset of these cases, likely a minority, given the multiple genetic subtypes of autosomal recessive cutis laxa. No specific registry data for *FBLN5*‑related cutis laxa are available, and the total number of reported ARCL1A patients worldwide likely numbers in the dozens rather than hundreds.[1][3][14]  

Because ARCL1A is so rare, population‑level incidence (new cases per 100,000 per year) cannot be accurately calculated, and most cases are identified via case reports or small series in specialized centers. Global burden of disease databases, national registries, and SEER do not track ARCL1A specifically due to its rarity. Orphanet may categorize ARCL1A as an ultra‑rare disease, but precise numbers are not given in the retrieved sources.[1][3][6][14]  

### 9.3 Population Demographics, Geographic Distribution, and Consanguinity

ARCL1A has been reported in families from various ethnic backgrounds, but specific geographic clustering or endemic regions have not been identified. Some cases arise in consanguineous families, as highlighted in the original Loeys et al. study of the S227P mutation, reflecting the increased risk of autosomal recessive disorders in populations with high consanguinity.[12][14][16] However, ARCL1A is not restricted to any single ethnic group or region, and its occurrence is sporadic worldwide.  

Carrier frequency for pathogenic *FBLN5* variants is unknown and likely extremely low globally. Population genetics databases such as gnomAD may show ultra‑rare *FBLN5* missense variants, but these are not necessarily pathogenic and comprehensive frequency data for known ARCL1A variants are not detailed in the retrieved resources.[6][11][14] There is no evidence of major founder mutations, although specific variants such as S227P have been reported in two likely related families, suggesting local clustering rather than widespread founder effects.[12][14][16]  

Sex ratio (male:female) data are limited, but ARCL1A does not appear to have a strong sex bias, as both males and females have been reported as affected in available case series.[3][14][16] Age distribution reflects congenital onset, so affected individuals are typically infants or children when diagnosed, with survival into adolescence or adulthood depending on severity of cardiopulmonary involvement.[1][3][14]  

---

## 10. Diagnostics

### 10.1 Clinical Evaluation, Laboratory Tests, and Imaging

Diagnosis of ARCL1A begins with clinical recognition of generalized cutis laxa and systemic features suggestive of a heritable elastic fiber disorder. Key clinical signs include redundant, sagging, inelastic skin, early‑onset pulmonary emphysema, peripheral pulmonary artery stenosis, and evidence of generalized connective tissue weakness such as hernias and diverticula.[1][2][3][14] A thorough physical examination should document cutaneous laxity, craniofacial features, joint laxity, and potential hernias, while family history should explore consanguinity and similar phenotypes in relatives.[2][3][14]  

Laboratory tests are typically nonspecific; routine blood work may be normal unless complications such as infection or hypoxia-induced organ dysfunction arise. Specific enzyme assays are not indicated for ARCL1A, as there is no known metabolic defect. Imaging studies, particularly chest X‑ray and CT, are critical to characterize pulmonary emphysema and assess lung architecture.[1][3][14] Echocardiography and Doppler ultrasound are used to evaluate peripheral pulmonary artery stenosis, supravalvar aortic stenosis, and cardiac function.[1][10][14] MRI or CT angiography may be employed for detailed vascular imaging in complex cases. Abdominal ultrasound, CT, or contrast studies can identify gastrointestinal and bladder diverticula and hernias.  

Functional tests, such as pulmonary function testing (spirometry, lung volumes, diffusion capacity), are important to quantify the severity of respiratory compromise and monitor progression, although they may be challenging in very young children.[1][14] ECG and possibly cardiac catheterization may be used to assess hemodynamic impact of vascular stenoses. No specific electrophysiologic tests (EEG, EMG) are typically necessary unless neurological symptoms suggest differential diagnoses like ARCL2A.[5][6][9]  

### 10.2 Histopathology and Biopsy Findings

Skin biopsy with histopathologic and ultrastructural analysis is highly informative in ARCL1A. Light microscopy shows decreased elastic fibers within the dermis, while electron microscopy reveals abnormal elastin components and disorganized elastic fibers.[2][3][16] MedGen and OMIM describe “diminution of elastic fibers throughout the dermis and abnormal elastin components by electron microscopy” as pathognomonic for autosomal recessive cutis laxa type I.[3][16] Altmeyer’s dermatology resource states that “electron microscopic reduction of elastic fibers in the dermis and abnormal elastin components is pathognomonic” for ARCL1A.[2]  

Hu et al. examined skin sections from a patient with homozygous S227P mutation and found a lack of fibulin‑5 in the ECM and disorganization of dermal elastic fibers, with electron microscopy showing failure of elastin globules to fuse into a continuous elastic fiber core.[16] These histopathologic findings not only confirm cutis laxa but also provide mechanistic insight into elastogenesis failure. Immunohistochemistry for fibulin‑5 may show absence of signal in the ECM, further supporting a diagnosis of *FBLN5*‑related cutis laxa.[16]  

### 10.3 Genetic Testing Strategies

Genetic testing is essential for definitive diagnosis of ARCL1A, given the phenotypic overlap with other cutis laxa syndromes and connective tissue disorders. GeneReviews for *FBLN5*‑related cutis laxa states that diagnosis is established in a proband with characteristic clinical features and biallelic *FBLN5* pathogenic variants identified by molecular testing.[14] Single‑gene testing (sequence analysis of *FBLN5*, followed by gene‑targeted deletion/duplication analysis) may be used when the phenotype strongly suggests ARCL1A and *FBLN5* involvement.[4][14]  

However, because the phenotype of cutis laxa may be indistinguishable from many other inherited disorders, multigene panels that include *FBLN5*, *EFEMP2*, *LTBP4*, *PYCR1*, *ATP6V0A2*, and other cutis laxa‑related genes are often recommended.[2][6][9][14] The ATP6V0A2‑related cutis laxa GeneReview specifically notes that single‑gene testing for *ATP6V0A2* is rarely useful and that multigene panels or comprehensive genomic testing (such as exome sequencing) are preferred due to phenotypic overlap.[6] This reasoning applies equally to ARCL1A, where distinguishing between *FBLN5*‑related and other forms based solely on clinical features can be difficult.  

Whole exome sequencing (WES) or whole genome sequencing (WGS) can detect *FBLN5* variants in undiagnosed patients with cutis laxa phenotypes, particularly when multigene panels are unavailable or inconclusive. The Genetic Testing Registry lists tests for *FBLN5* and ARCL1A, providing laboratory options.[4] Chromosomal microarray, karyotyping, FISH, and mitochondrial DNA testing are not typically helpful, as ARCL1A is caused by sequence‑level variants rather than chromosomal or mitochondrial abnormalities.[3][4][14]  

Once *FBLN5* pathogenic variants are identified in an affected family member, carrier testing for at‑risk relatives, prenatal testing for pregnancies at increased risk, and preimplantation genetic testing become possible, as noted for EFEMP2‑related cutis laxa and by analogy for *FBLN5*.[7][14]  

### 10.4 Differential Diagnosis and Clinical Criteria

Differential diagnosis for ARCL1A includes other hereditary cutis laxa syndromes and connective tissue disorders such as Marfan syndrome and Ehlers‑Danlos syndrome. Autosomal recessive cutis laxa type 1B (EFEMP2‑related) presents with cutis laxa plus systemic involvement, most commonly arterial tortuosity, aneurysms, and stenosis, retrognathia, joint laxity, and arachnodactyly.[7] Autosomal recessive cutis laxa type 2A (ATP6V0A2‑related) features generalized cutis laxa, developmental delay, seizures, and brain malformations, distinguishing it from ARCL1A, which usually lacks neurologic abnormalities.[5][6][9]  

Marfan syndrome and Ehlers‑Danlos syndrome share connective tissue fragility, but in Marfan, skin is not typically pendulous and inelastic as in cutis laxa, and the primary defects involve fibrillin‑1 or collagen, respectively.[2][3] Wrinkly skin syndrome and De Barsy syndrome also show cutis laxa but have distinct genetic and phenotypic profiles, often involving ATP6V0A2 and additional neurologic or ophthalmologic features.[6][9][17]  

Standardized diagnostic criteria for ARCL1A have not been formally codified in society guidelines, but GeneReviews and OMIM provide practical criteria: generalized cutis laxa, early‑onset pulmonary emphysema, vascular anomalies (especially peripheral pulmonary artery stenosis), diverticula, hernias, and biallelic pathogenic *FBLN5* variants.[1][3][14]  

### 10.5 Screening

Population‑level screening for ARCL1A is not currently feasible or indicated due to its extreme rarity. Newborn screening programs do not include ARCL1A. However, targeted genetic screening may be appropriate for at‑risk families, including carrier testing of relatives of affected individuals and prenatal or preimplantation genetic diagnosis when familial *FBLN5* mutations are known.[7][11][14] Carrier screening in high‑consanguinity populations could theoretically identify *FBLN5* variants, but no formal programs exist. Clinical surveillance of known ARCL1A patients focuses on early detection of cardiopulmonary and visceral complications rather than screening for the disease itself.[1][3][14]  

---

## 11. Outcome and Prognosis

### 11.1 Survival, Mortality, and Life Expectancy

Prognosis in ARCL1A is primarily determined by the severity of pulmonary and cardiovascular involvement. MedGen and GeneReviews state that cardiorespiratory failure from complications of pulmonary emphysema is the most common cause of death in *FBLN5*‑related cutis laxa.[1][14] Early childhood‑onset emphysema can lead to respiratory failure, hypoxia, and heart strain, particularly when compounded by peripheral pulmonary artery stenosis and supravalvar aortic stenosis.[1][3][10][14]  

Life expectancy varies widely depending on disease severity and access to advanced care. Some infants with severe ARCL1A may die in the perinatal period or early infancy due to overwhelming cardiopulmonary compromise, while others survive into childhood or adolescence with chronic respiratory and cardiovascular management.[1][3][14] Precise survival rates and median life expectancy are not available due to the small number of reported cases and lack of longitudinal cohort studies. Mortality rates are not tracked in national registries or global burden of disease datasets, reflecting the ultra‑rare nature of the condition.[1][3][6][14]  

### 11.2 Morbidity, Disability, and Quality of Life

Morbidity in ARCL1A is substantial, encompassing chronic respiratory symptoms, exercise intolerance, recurrent infections, and complications from vascular stenosis and organ diverticula. Functional impairment can be profound, limiting physical activity and requiring supplemental oxygen, frequent hospitalizations, and invasive interventions such as surgeries for hernias or vascular lesions.[1][2][3][14]  

Disability outcomes include long‑term dependence on caregivers, restricted participation in normal childhood activities, and possible cognitive impacts from chronic hypoxia, although intrinsic neurodevelopmental defects are not typical of ARCL1A.[3][14] Quality of life is affected not only by physical limitations but also by psychosocial issues related to appearance (due to cutis laxa) and chronic illness. Formal QoL measures such as SF‑36, EQ‑5D, or PROMIS have not been systematically applied to ARCL1A patients, but extrapolation from similar chronic cardiopulmonary diseases suggests significant reductions in multiple domains of well‑being.[1][3][14]  

### 11.3 Disease Course, Complications, and Recovery Potential

Complications of ARCL1A include recurrent respiratory infections, respiratory failure requiring mechanical ventilation or long‑term oxygen therapy, right heart failure and pulmonary hypertension due to pulmonary artery stenosis and emphysema, aneurysm or dissection of affected arteries, gastrointestinal obstruction or perforation due to diverticula, urinary tract infections associated with bladder diverticula, and incarceration or strangulation of hernias.[1][2][3][10][14]  

Recovery potential is limited, as the underlying elastic fiber defect cannot be reversed with current therapies. Supportive care can stabilize symptoms, prevent or treat complications, and, in some cases, significantly prolong survival. For example, surgical correction of pulmonary artery stenosis or supravalvar aortic stenosis may improve hemodynamics, and repair of hernias or diverticula can prevent life‑threatening events.[1][10][14] Lung transplantation has not been specifically reported for ARCL1A, but theoretically could be considered in selected cases with severe emphysema. However, the systemic nature of elastic fiber defects raises concerns about long‑term outcomes.  

### 11.4 Prognostic Factors and Biomarkers

Prognostic factors include severity of pulmonary emphysema (quantified by imaging and pulmonary function tests), degree of peripheral pulmonary artery and aortic stenosis (assessed by echocardiography and catheterization), presence and extent of diverticula and hernias, and overall nutritional and developmental status.[1][3][10][14] Early recognition and aggressive management of cardiopulmonary complications may improve outcomes. There are no established molecular prognostic biomarkers specific to ARCL1A, though general markers of cardiac and pulmonary function (e.g., NT‑proBNP, arterial blood gases) may be used to monitor disease course.  

Genotype–phenotype correlations are limited but may influence prognosis; for example, nonsense variants causing complete loss of fibulin‑5 might be associated with more severe disease than certain missense variants, though small case numbers preclude definitive statements. Further studies are needed to clarify whether specific *FBLN5* mutations predict milder or more severe phenotypes.[14][16]  

---

## 12. Treatment

### 12.1 Pharmacotherapy and Supportive Medical Management

There is no disease‑specific pharmacotherapy that corrects the underlying fibulin‑5 defect in ARCL1A. Treatment is primarily supportive and organ‑based, focusing on management of pulmonary emphysema, vascular anomalies, and connective tissue complications.[1][3][14]  

Pulmonary management includes bronchodilators, inhaled corticosteroids if airway inflammation is present, supplemental oxygen for hypoxemia, and prompt antibiotic therapy for respiratory infections, following general guidelines for pediatric chronic lung disease and emphysema.[1][14] Progressive respiratory failure may necessitate noninvasive or invasive ventilatory support. NCIT terms relevant to pulmonary management include “Respiratory therapy” (NCIT:C15365) and “Oxygen therapy” (NCIT:C50683).  

Cardiovascular management targets peripheral pulmonary artery stenosis and supravalvar aortic stenosis. Medical treatment may involve diuretics, ACE inhibitors, or other heart failure medications to manage symptoms, though these do not correct anatomical stenoses. NCIT terms include “Cardiac therapy” (NCIT:C15402) and “Vasodilator therapy” (NCIT:C71434). Specific pharmacologic regimens for ARCL1A have not been studied systematically and are based on standard pediatric cardiology practice.[1][10][14]  

Pain management, nutritional support, and physiotherapy are important supportive components, addressing symptoms and maintaining growth and function. NCIT terms such as “Supportive care” (NCIT:C307) and “Palliative care” (NCIT:C18478) may apply in advanced disease.  

### 12.2 Surgical and Interventional Therapies

Surgical and interventional procedures play a key role in managing structural complications of ARCL1A. Peripheral pulmonary artery stenosis may be treated with balloon angioplasty or stent placement via cardiac catheterization, and supravalvar aortic stenosis may require surgical repair (e.g., patch aortoplasty).[1][10][14] NCIT terms for such procedures include “Angioplasty” (NCIT:C15278), “Stent placement” (NCIT:C15242), and “Cardiac surgery” (NCIT:C15795).  

Inguinal hernias and other abdominal wall hernias are generally repaired surgically to prevent incarceration or strangulation. Diverticula of the intestine or bladder may require surgical or endoscopic intervention if they cause obstruction, perforation, or recurrent infections. Orthopedic surgery may be indicated for hip dislocation or other joint abnormalities, such as open or closed reduction and stabilization procedures. These surgeries follow standard practice guidelines, but surgeons must consider connective tissue fragility due to elastic fiber defects in planning and performing operations.[1][2][3][14]  

### 12.3 Advanced Therapeutics and Experimental Approaches

No gene therapy, cell therapy, or targeted molecular therapy is currently approved or in clinical trials specifically for ARCL1A. In principle, gene replacement or gene editing strategies targeting *FBLN5* could restore normal fibulin‑5 production in fibroblasts and ECM‑producing cells, but the systemic distribution of affected tissues and the complex requirements of elastogenesis pose significant challenges. Delivery of functional FBLN5 to skin, lung, and vasculature would require sophisticated vector systems and tissue‑specific expression control.  

Experimental approaches in animal models, such as Fbln5 knockout mice, may explore viral vector‑mediated Fbln5 expression or small molecules that modulate elastogenesis, but such studies are at an early stage and none have reached human trials.[13][15] RNA‑based therapies (e.g., antisense oligonucleotides, siRNA) are unlikely to be beneficial in loss‑of‑function ARCL1A, since the problem is absence of functional protein, not toxic gain of function. Stem cell or mesenchymal cell therapies are theoretically conceivable but have not been studied in this context.  

### 12.4 Treatment Outcomes and Personalized Medicine

Treatment outcomes in ARCL1A are variable and depend on the severity of disease and availability of specialized care. Surgical correction of vascular stenosis and hernias can be successful and improve quality of life, but underlying connective tissue fragility may predispose to recurrent or residual issues. Pulmonary management can stabilize symptoms but rarely reverses emphysematous changes; long‑term outcomes for severe emphysema remain guarded.[1][3][10][14]  

Personalized medicine approaches in ARCL1A currently center on genotype‑guided diagnosis and familial risk assessment rather than genotype‑specific therapy. Knowledge of the specific *FBLN5* mutation allows accurate carrier testing and reproductive planning, but does not yet inform tailored pharmacologic treatment. As research advances, it is possible that subtle genotype–phenotype correlations could support individualized prognostic counseling.

---

## 13. Prevention

### 13.1 Primary Prevention: Genetic Counseling and Reproductive Options

Primary prevention of ARCL1A focuses on genetic counseling and reproductive planning for families with known *FBLN5* pathogenic variants. GeneReviews for *FBLN5*‑related cutis laxa emphasizes the importance of identifying at‑risk couples, particularly in consanguineous families, and offering carrier testing.[14] Once familial *FBLN5* mutations are known, carrier testing of siblings and extended family members can inform reproductive risk. Prenatal testing via chorionic villus sampling or amniocentesis, and preimplantation genetic testing (PGT) during in vitro fertilization, can be offered to couples at high risk to prevent the birth of affected children.[7][11][14]  

These interventions require informed counseling about disease severity, prognosis, and available management options. They also involve ethical considerations and personal values regarding reproductive decision‑making. NCIT terms relevant to these procedures include “Genetic counseling” (NCIT:C17564), “Prenatal diagnosis” (NCIT:C17010), and “Preimplantation genetic testing” (NCIT:C17302).  

### 13.2 Secondary and Tertiary Prevention

Secondary prevention in ARCL1A involves early detection of disease in newborns or infants with family history or suggestive clinical signs, enabling timely intervention for pulmonary and cardiovascular complications. While newborn screening for ARCL1A is not available, targeted screening via physical examination, imaging, and, when indicated, genetic testing can identify affected infants early.[1][3][14]  

Tertiary prevention focuses on preventing complications and minimizing disability in individuals already affected by the disease. Strategies include rigorous management of respiratory infections, vaccination against respiratory pathogens, careful monitoring for vascular stenosis and aneurysms, and surgical correction of hernias and diverticula before catastrophic events occur. Lifestyle modifications such as avoiding tobacco smoke and severe air pollution, maintaining good nutrition, and adhering to medical regimens are supportive tertiary measures.[1][14]  

### 13.3 Public Health and Environmental Interventions

Given the ultra‑rare nature of ARCL1A, public health interventions are not tailored specifically to this disease but fall under broader programs for rare disease awareness, genetic counseling, and environmental health. Reducing environmental risk factors for lung disease, such as air pollution and tobacco use, may indirectly benefit ARCL1A patients by limiting secondary damage to compromised lungs. Education of healthcare providers about hereditary cutis laxa syndromes can improve recognition and referral for specialized care.[1][2][3][14]  

---

## 14. Other Species and Natural Disease

### 14.1 Orthologous Genes and Animal Disease

Orthologous genes for *FBLN5* exist in multiple species, including mice (*Fbln5*), rats, and other vertebrates.[12][13] Fbln5 knockout mice provide a key model for studying elastic fiber defects and tissue mechanics, offering insights into the role of fibulin‑5 in tendon, lung, and arterial physiology.[13]  

Naturally occurring cutis laxa‑like diseases in companion animals or livestock have not been well documented in the literature, and OMIA (Online Mendelian Inheritance in Animals) does not list specific fibulin‑5‑related disorders in animals based on the retrieved resources. However, given the conserved role of elastic fibers and ECM across mammals, it is plausible that rare spontaneous mutations in *Fbln5* or related genes could cause analogous phenotypes in animals, though such cases may be underrecognized or unreported.[12][13]  

### 14.2 Comparative Pathology and Evolutionary Conservation

Comparative pathology studies in Fbln5 knockout mice demonstrate malformed elastic fibers and altered tissue mechanics, supporting the notion that fibulin‑5 is evolutionarily conserved in its role as an elastogenic scaffold.[13] These mice show disconnected elastin globules instead of dense elastic fiber cores in tendons, similar to the human skin findings in ARCL1A patients.[13][16] Such comparative data strengthen the mechanistic understanding of fibulin‑5 function and its importance across species.  

HomoloGene and other orthology databases would classify human *FBLN5* and mouse *Fbln5* in a conserved gene family involved in ECM organization and elastic fiber formation, underscoring evolutionary conservation of disease mechanisms. There is no known zoonotic potential for ARCL1A, as it is a non‑infectious genetic disorder.  

---

## 15. Model Organisms

### 15.1 Mouse Models of Fibulin‑5 Deficiency

Fbln5 knockout mice are the primary model organism for studying fibulin‑5 function and elastic fiber pathology. These mice exhibit malformed elastic fibers in multiple tissues, including tendons, and alterations in mechanical properties such as increased elastic modulus in a tendon-specific manner.[13] Transmission electron microscopy confirms the presence of malformed elastic fibers in knockout tendons, with disconnected elastin globules instead of normal dense cores, paralleling findings in human ARCL1A skin.[13][16]  

Papke and Yanagisawa reviewed fibulin‑4 and fibulin‑5 in elastogenesis and noted that Fbln5‑deficient mice show severe arterial and lung phenotypes, including aortic aneurysms and emphysematous lung changes, providing a strong mechanistic model for human FBLN5‑related disease.[13] Fibulin‑5’s role in vasculogenesis and vascular remodeling further supports the relevance of mouse models for ARCL1A’s vascular manifestations.[12][13][15]  

### 15.2 Model Characteristics: Recapitulation and Limitations

Fbln5 knockout mice recapitulate key features of human fibulin‑5 deficiency, including defective elastic fiber assembly, tissue mechanical alterations, and vascular abnormalities. The tendon study showed that, in the absence of fibulin‑5, elastic fibers are dysregulated and form disconnected globules, while overall tendon composition remains otherwise normal, emphasizing the specificity of fibulin‑5’s role in elastogenesis.[13]  

These models capture the core mechanistic defect but do not map exactly onto the full human ARCL1A phenotype, particularly regarding generalized cutis laxa and specific pulmonary and cardiovascular manifestations. Differences in species physiology and lifespan may limit direct translation of certain features, such as the timing and severity of emphysema or the spectrum of vascular lesions. Nevertheless, Fbln5 knockout mice are invaluable for testing hypotheses about fibulin‑5 function, ECM dynamics, and potential therapeutic interventions.[13][15][16]  

### 15.3 Applications in Research

Mouse models of fibulin‑5 deficiency are used to study:

1. Elastic fiber assembly and ECM organization in vivo.  
2. Tissue mechanics and the role of elastic fibers in tendon, lung, and arterial function.  
3. Vascular remodeling, endothelial cell behavior, and response to hypoxia in the absence of functional fibulin‑5.[13][15]  
4. Potential therapeutic interventions targeting elastogenesis, ECM stabilization, or pathway modulation.  

These models allow detailed histologic, ultrastructural, and biomechanical analyses that are difficult to perform in human patients, and they can be used to test candidate treatments or gene therapy approaches in controlled settings. Their limitations include species differences and the inability to fully replicate complex human social and environmental contexts, but they remain essential for mechanistic research.  

---

## Conclusion

Autosomal recessive cutis laxa type 1A (ARCL1A) is a paradigmatic Mendelian disorder of elastic fiber assembly, caused by biallelic loss‑of‑function mutations in *FBLN5*, encoding fibulin‑5, a central organizer of elastogenesis in skin, lung, vasculature, and other connective tissues.[1][3][11][12][14][16] The disease manifests as generalized cutis laxa with redundant, inelastic skin, early childhood‑onset pulmonary emphysema, peripheral pulmonary artery stenosis, hollow viscus diverticula, and hernias, with cardiorespiratory failure from emphysema complications being the most common cause of death.[1][2][3][14] Mechanistically, recessive *FBLN5* variants cause fibulin‑5 misfolding, ER retention, reduced secretion, and impaired binding to tropoelastin and fibrillin‑1, leading to disorganized elastic fibers and failure of elastogenesis, as shown by patient fibroblast studies and mouse models.[12][13][15][16]  

Despite significant advances in understanding the molecular and cellular basis of ARCL1A, clinical management remains supportive and organ‑focused, with no disease‑modifying therapies currently available. Genetic diagnosis via *FBLN5* sequencing and multigene panels is crucial for distinguishing ARCL1A from other cutis laxa syndromes and connective tissue disorders, guiding prognosis and enabling carrier testing, prenatal diagnosis, and preimplantation genetic testing.[3][4][6][7][11][14] Future research directions include deeper exploration of fibulin‑5’s interactions with integrins and ECM components, development of targeted therapies that restore or mimic fibulin‑5 function, and expanded use of Fbln5 knockout and other model organisms to test therapeutic strategies.  

From a knowledge base perspective, ARCL1A provides a rich example of how single‑gene defects in ECM organization can produce multi‑organ disease, reinforcing the importance of integrating genetic, molecular, cellular, and clinical data to fully characterize rare disorders. Ontology‑based annotations using MONDO, HPO, GO, CL, and UBERON terms can capture the complex phenotypic and mechanistic landscape of ARCL1A, enabling computational analyses and cross‑disease comparisons. As genomic sequencing becomes more widespread, additional ARCL1A patients and *FBLN5* variants will likely be identified, broadening our understanding of genotype–phenotype correlations and potentially revealing new avenues for precision medicine in elastic fiber disorders.

## Reference Validation

Checked with `linkml-reference-validator` 0.3.0.

| Outcome | Count |
| --- | --- |
| References checked | 4 |
| Resolved | 4 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| Quoted claims checked | 2 |
| Quoted claims found in source | 2 |
| Quoted claims **not** found in source | 0 |
| References weighed for topical relevance | 4 |
| On topic | 3 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 69 |
| Resolved | 63 |
| Unresolved (possible confabulation) | 2 |
| Obsolete | 2 |
| Unverifiable | 2 |
| Terms whose name was checked | 12 |
| Terms named correctly | 0 |
| Terms named as a **different** term | 12 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `NCIT:C15365` (1 mention) - the report calls it "Respiratory therapy"; NCIT calls it **Outcomes Research**
- `NCIT:C50683` (1 mention) - the report calls it "Oxygen therapy"; NCIT calls it **Device Overstimulation**
- `NCIT:C15402` (1 mention) - the report calls it "Cardiac therapy"; NCIT calls it **Conization**
- `NCIT:C71434` (1 mention) - the report calls it "Vasodilator therapy"; NCIT calls it **COL4A5 wt Allele**
- `NCIT:C307` (1 mention) - the report calls it "Supportive care"; NCIT calls it **Biological Agent**
- `NCIT:C18478` (1 mention) - the report calls it "Palliative care"; NCIT calls it **Nanotechnology**
- `NCIT:C15278` (1 mention) - the report calls it "Angioplasty"; NCIT calls it **Modified Radical Mastectomy**
- `NCIT:C15242` (1 mention) - the report calls it "Stent placement"; NCIT calls it **Health Maintenance Organization**
- `NCIT:C15795` (1 mention) - the report calls it "Cardiac surgery"; NCIT calls it **Detection of Measurable Residual Disease**
- `NCIT:C17564` (1 mention) - the report calls it "Genetic counseling"; NCIT calls it **Guideline**
- `NCIT:C17010` (1 mention) - the report calls it "Prenatal diagnosis"; NCIT calls it **Prevalence**
- `NCIT:C17302` (1 mention) - the report calls it "Preimplantation genetic testing"; NCIT calls it **Histone Acetylase**

### Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

- `HP:0004424` (1 mention) - HP does not contain this term
- `HP:0005118` (1 mention) - HP does not contain this term

### Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

- `HP:0001388` (obsolete Joint laxity) (1 mention) - replaced by `HP:0001382`
- `GO:0030433` (obsolete ubiquitin-dependent ERAD pathway) (1 mention) - replaced by `GO:0036503`